[-] Show simple item record

dc.contributor.authorBossenbroek, Kellyeng
dc.contributor.authorMounsey, Anne L.eng
dc.contributor.otherFamily Physicians Inquiries Networkeng
dc.date.issued2011eng
dc.description.abstractPrescribe a mineralocorticoid-receptor antagonist for patients with New York Heart Association (NYHA) Class II systolic heart failure and an ejection fraction (EF) ≤30%. Eplerenone has been found to decrease hospitalizations for heart failure and cardiovascular and all-cause mortality. Stength of recommendation: A: Based on one high-quality randomized controlled trial (RCT).eng
dc.identifier.urihttp://hdl.handle.net/10355/11372
dc.languageEnglisheng
dc.publisherFamily Physicians Inquiries Networkeng
dc.relation.ispartofcollectionPriority Updates to Research Literature (PURLs) (2011)eng
dc.relation.ispartofcommunityUniversity of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Networkeng
dc.relation.ispartofseriesJournal of family practice, 60, no. 08 (August 2011): 482+.eng
dc.rightsOpenAccess.eng
dc.rights.licenseThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.eng
dc.subjectheart failureeng
dc.subjectmyocardial infarctioneng
dc.subjecthyperkalemiaeng
dc.subject.lcshHeart failureeng
dc.subject.lcshMyocardial infarctioneng
dc.subject.lcshSpironolactoneeng
dc.titleMore help for patients with less severe heart failureeng
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record